Inhaled Dry Powder Mannitol: A Solution for Cystic Fibrosis

被引：4
|
作者：
Trapnell, Bruce C. [1 ]
机构：
[1] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2012年 / 185卷 / 06期
关键词：
HYPERTONIC SALINE; CLEARANCE;
D O I：
10.1164/rccm.201112-2205ED
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：596 / 598
页数：4
相关论文
共 50 条
  • [21] Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis
    Riedler, J
    Reade, T
    Button, B
    Robertson, CF
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 1996, 32 (01) : 48 - 50
  • [22] Inhaled treatments in cystic fibrosis: What's new in 2013?
    Dubus, J-C
    Bassinet, L.
    Chedevergne, F.
    Delaisi, B.
    Desmazes-Dufeu, N.
    Reychler, G.
    Vecellio, L.
    REVUE DES MALADIES RESPIRATOIRES, 2014, 31 (04) : 336 - 346
  • [23] The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline
    John D Brannan
    Sandra D Anderson
    Clare P Perry
    Ruth Freed-Martens
    Anna R Lassig
    Brett Charlton
    Respiratory Research, 6
  • [24] Mannitol-Guided Delivery of Ciprofloxacin in Artificial Cystic Fibrosis Mucus Model
    Yang, Yan
    Tsifansky, Michael D.
    Shin, Sooyoung
    Lin, Qingnuo
    Yeo, Yoon
    BIOTECHNOLOGY AND BIOENGINEERING, 2011, 108 (06) : 1441 - 1449
  • [25] Inhaled Hypertonic Saline in Infants and Toddlers With Cystic Fibrosis: Short-Term Tolerability, Adherence, and Safety
    Rosenfeld, Margaret
    Davis, Stephanie
    Brumback, Lyndia
    Daniel, Stephen
    Rowbotham, Ron
    Johnson, Robin
    McNamara, Sharon
    Jensen, Renee
    Barlow, Carol
    Ratjen, Felix
    PEDIATRIC PULMONOLOGY, 2011, 46 (07) : 666 - 671
  • [26] Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis
    Subbarao, Padmaja
    Balkovec, Susan
    Solomon, Melinda
    Ratjen, Felix
    PEDIATRIC PULMONOLOGY, 2007, 42 (05) : 471 - 476
  • [27] INHALED MUCOACTIVE DRUGS FOR TREATING NON-CYSTIC FIBROSIS BRONCHIECTASIS IN CHILDREN
    Snijders, D.
    Calgaro, S.
    Bertozzi, I.
    Quartesan, S.
    Kozuh, I.
    Lunardi, F.
    Barbato, A.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2013, 26 (02) : 529 - 534
  • [28] Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study
    Matloka, Mikolaj
    Janowska, Sylwia
    Gajos-Draus, Anna
    Ziolkowski, Hubert
    Janicka, Monika
    Perko, Przemyslaw
    Kamil, Kislo
    Pankiewicz, Piotr
    Moszczy, Rafal
    Mach, Mateusz
    Dera, Paulina
    Abramski, Krzysztof
    Teska-Kaminska, Malgorzata
    Tratkiewicz, Ewa
    Wieczorek, Maciej
    Pieczykolan, Jerzy
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2022, 73
  • [29] A Novel In-Line Delivery System to Administer Dry Powder Mannitol to Mechanically Ventilated Patients
    Feng, Benny
    Tang, Patricia
    Leung, Sharon Shui Yee
    Dhanani, Jayesh
    Chan, Hak-Kim
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2017, 30 (02) : 100 - 107
  • [30] AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis
    Kristensson, Cecilia
    Astrand, Annika
    Donaldson, Scott
    Goldwater, Ron
    Abdulai, Raolat
    Patel, Naimish
    Gardiner, Philip
    Tehler, Ulrika
    Mercier, Anne-Kristina
    Olsson, Marita
    Ersdal, Eva
    Maenpaa, Jukka
    Bramer, Tobias
    Malmgren, Anna
    Bennett, William
    Keen, Christina
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (04) : 684 - 690
12345